Evaluation of antibody testing for
SARS-CoV-2 using ELISA and lateral flow immunoassays

AUTHORSHIP: National COVID Testing Scientific Advisory Panel*

*The authors’ names, degrees and affiliations are provided at the end of manuscript.

KEYWORDS: COVID-19, SARS-CoV-2, serology, IgG, IgM, antibodies, immunoassay, ELISA, lateral flow, exposure, epidemiology

RUNNING HEAD: Serological assays for SARS-CoV-2

CORRESPONDING AUTHOR:
Prof Derrick Crook
Department of Microbiology, John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom
derrick.crook@ndcls.ox.ac.uk

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
ABSTRACT

Background: The SARS-CoV-2 pandemic caused >1 million infections during January-March 2020. There is an urgent need for robust antibody detection approaches to support diagnostics, vaccine development, safe individual release from quarantine and population lock-down exit strategies. The early promise of lateral flow immunoassay (LFIA) devices has been questioned following concerns about sensitivity and specificity.

Methods: We used a panel of plasma samples designated SARS-CoV-2 positive (from SARS-CoV-2 RT-PCR-positive individuals; n=40) and negative (samples banked in the UK prior to December-2019 (n=142)). We tested plasma for SARS-CoV-2 IgM and IgG antibodies by ELISA and using nine different commercially available LFIA devices.

Results: ELISA detected SARS-CoV-2 IgM or IgG in 34/40 individuals with an RT-PCR-confirmed diagnosis of SARS-CoV-2 infection (sensitivity 85%, 95%CI 70-94%), vs 0/50 pre-pandemic controls (specificity 100% [95%CI 93-100%]). IgG levels were detected in 31/31 RT-PCR-positive individuals tested ≥10 days after symptom onset (sensitivity 100%, 95%CI 89-100%). IgG titres rose during the 3 weeks post symptom onset and began to fall by 8 weeks, but remained above the detection threshold. Point estimates for the sensitivity of LFIA devices ranged from 55-70% versus RT-PCR and 65-85% versus ELISA, with specificity 95-100% and 93-100% respectively. Within the limits of the study size, the performance of most LFIA devices was similar.

Conclusions: The performance of current LFIA devices is inadequate for most individual patient applications. ELISA can be calibrated to be specific for detecting and quantifying SARS-CoV-2 IgM and IgG and is highly sensitive for IgG from 10 days following symptoms onset.
INTRODUCTION

The first cases of infection with a novel coronavirus, subsequently designated SARS-CoV-2, emerged in Wuhan, China on December 31, 2019. Despite intensive containment efforts, there was rapid international spread and three months later, SARS-CoV-2 had caused over 1 million confirmed infections and 60,000 reported deaths.

Containment efforts have relied heavily on population quarantine ('lock-down') measures to restrict movement and reduce individual contacts. To develop public health strategies for exit from lock-down, diagnostic testing urgently needs to be scaled-up, including both mass screening and screening of specific high-risk groups (contacts of confirmed cases, and healthcare workers and their families), in parallel with collecting robust data on recent and past SARS-CoV-2 exposure at individual and population levels.

Laboratory diagnosis of infection has mostly been based on real-time RT-PCR, typically targeting the viral RNA-dependent RNA polymerase (RdRp) or nucleocapsid (N) genes using swabs collected from the upper respiratory tract. This requires specialist equipment, skilled laboratory staff and PCR reagents, creating diagnostic delays. RT-PCR from upper respiratory tract swabs may also be falsely negative due to quality or timing; viral loads in upper respiratory tract secretions peak in the first week of symptoms, but may have declined below the limit of detection in those presenting later. In individuals who have recovered, RT-PCR provides no information about prior exposure or immunity.

In contrast, assays that reliably detect antibody responses specific to SARS-CoV-2 could contribute to diagnosis of acute infection (via rises in IgM and IgG levels) and to identifying those infected with or without symptoms and recovered (via persisting IgG). Receptor-mediated viral entry to host cells occurs through interactions between the unique and highly-conserved SARS-CoV-2 spike (S) glycoprotein and the ACE2 cell receptor. This S protein is the primary target of specific neutralising antibodies, and current SARS-CoV-2 serology assays therefore typically seek to identify these antibodies (Figure 1A-C). Rapid lateral flow immunoassay (LFIA) devices provide a quick, point-of-care approach to antibody testing. A sensitive and specific antibody assay could directly contribute to early identification and
isolation of cases, address unknowns regarding the extent of infection to inform mathematical models and support individual or population-level release from lock-down.

However, before either laboratory assays or LFIA devices can be widely deployed, their performance characteristics need to be evaluated (Figure 1D,E).\textsuperscript{11} We therefore compared a novel laboratory-based ELISA assay with nine commercially-available LFIA devices using samples from patients with RT-PCR-confirmed SARS-CoV-2 infection, and negative pre-pandemic samples.

METHODS

Samples

142 plasma samples designated seronegative for SARS-CoV-2 were collected from adults (≥18 years) in the UK before December 2019 (Table S1) from three ethically approved sources: healthy blood donors, organ donors on ICU following cerebral injury and healthy volunteers from a vaccine study, BERT.

Forty plasma samples were collected from adults positive for SARS-CoV-2 by RT-PCR from an upper respiratory tract (nose/throat) swab tested in accredited laboratories (Table S1). Acute (≤28 days from symptom onset) and convalescent samples (>28 days) were included to optimise detection of SARS-CoV-2 specific IgM and IgG respectively (Figure 1B). Acute samples were collected from patients a median 10 (range 4-27) days from symptom onset (n=16), and from recovering healthcare workers median 13 [range 8-19] days after first symptoms; (n=6). Convalescent samples were collected from adults a median 48 [range 31-62] days after symptom onset and/or date of positive throat swab (n=18). Further sample details in Supplementary Material.

Cases were classified following WHO criteria as critical (respiratory failure, septic shock, and/or multiple organ dysfunction/failure); severe (dyspnoea, respiratory frequency ≥30/minute, blood oxygen saturation ≤93%, PaO\textsubscript{2}/FiO\textsubscript{2} ratio <300, and/or lung infiltrates >50% of the lung fields within 24-48 hours); or otherwise mild.\textsuperscript{12} Among 22 acute cases, 9 were critical, 4 severe and 9 mild. All but one convalescent individual had mild disease; the other was asymptomatic and screened during enhanced contact tracing.
Enzyme-linked immunosorbent assay (ELISA)
We used a novel ELISA. Recombinant SARS-CoV-2 trimeric spike protein was constructed, tagged and purified. Immunoplates coated with StrepMAB-Classic were used to capture tagged soluble trimeric SARS-CoV-2 trimeric S protein and then incubated with test plasma. Antibody binding to the S protein was detected with ALP-conjugated anti-human IgG or anti-human IgM. (Further details in Supplementary Material.)

Lateral flow immunoassays (LFIA)
We tested LFIA devices designed to detect IgM, IgG or total antibodies to SARS-CoV-2 produced by nine manufacturers short-listed as a testing priority by the UK Government Department of Health and Social Care (DHSC), based on appraisals of device provenance and available performance data. Individual manufacturers did not approve release of device-level data, so device names are anonymised.

Testing was performed in strict accordance with the manufacturer’s instructions for each device. Typically, this involved adding 5-20µl of plasma to the sample well, and 80-100µl of manufacturer’s buffer to an adjacent well, followed by incubation at room temperature for 10-15 minutes. The result was based on the appearance of coloured bands, designated as positive (control and test bands present), negative (control band only), or invalid (no band, absent control band, or band in the wrong place) (Figure 1C).

We recorded results in real-time on a password-protected electronic database, using pseudonymised sample identifiers, capturing the read-out from the device (positive/negative/invalid), operator, device, device batch number, and a timestamped photograph of the device.

Testing protocol
We tested 90 samples using ELISA to quantify IgM and IgG antibody in plasma designated SARS-CoV-2 negative (n=50) and positive (n=40). All positive samples were included and an unstratified random sample of negative plasma from healthy blood donors (n=23) and organ donors (n=27). We tested the nine different LFIA devices using between 39-165 individual
plasma samples (8-23 and 31-142 samples designated SARS-CoV-2 positive and negative, respectively, Table S2). Total numbers varied according to the number of devices supplied to the DHSC; samples were otherwise selected at random.

**Statistical analysis**
Analyses were conducted using R (version 3.6.3) and Stata (version 15.1), with additional plots generated using GraphPad Prism (version 8.3.1). Binomial 95% confidence intervals (CI) were calculated for all proportions. The association between ELISA results and time since symptom onset, severity, need for hospital admission and age was estimated using multivariable linear regression, without variable selection. Non-linearity in relationships with continuous factors was included via natural cubic splines. Differences between LFIA devices were estimated using mixed effects logistic regression models, allowing for each device being tested on overlapping sample sets. Differences between devices were compared with Benjamini-Hochberg corrected p-value thresholds. (Further details in Supplementary Material.)

**RESULTS**
**Detection of SARS-CoV-2 IgM and IgG antibody by ELISA**
Forty positive (RT-PCR-confirmed SARS-CoV-2 infection) and 50 designated negative (pre-pandemic) plasma samples were tested by ELISA to characterise antibody profiles. Negative samples had median optical density (OD) for IgM of -0.0001 (arbitrary units) (range -0.14 to 0.06) and for IgG -0.01 (range -0.38 to 0.26). The median IgM reading in 40 positive samples was 0.18 (range -0.008 to 1.13; Kruskal-Wallis p<0.001 vs. negative) and IgG median 3.0 (range -0.2 to 3.5; p<0.001).

As safe individual release from lock-down is a major application for serological testing, we chose OD thresholds that maintained 100% specificity (95%CI 93-100%), while maximising sensitivity. Using thresholds of 0.07 for IgM and 0.4 for IgG (3 and 5 standard deviations above the negative mean respectively; Figure 2A,B), the IgG assay had 85% sensitivity (95%CI 70-94%; 34/40) vs. RT-PCR diagnosis. All six false-negatives were from samples taken within 9 days of symptom onset (Figure 2D). IgG levels were detected in 31/31 RT-PCR-positive individuals tested ≥10 days after symptom onset (sensitivity 100%, 95%CI 89-100%). The IgM
assay sensitivity was lower at 70% (95%CI 53-83%; 28/40). All IgG false-negatives were IgM-negative. No patient was IgM-positive and IgG-negative.

Considering the relationship between IgM and IgG titres and time since symptom onset (Figures 2C,D), univariable regression models showed IgG antibody titres rising over the first 3 weeks from symptom onset. The lower bound of the pointwise 95%CI for the mean expected titre crosses our OD threshold between days 6-7 (Figure 2D). However, given sampling variation, test performance is likely to be optimal from several days later. IgG titres fell during the second month after symptom onset but remained above the OD threshold. No temporal association was observed between IgM titres and time since symptom onset (Figure 2C). There was no evidence that SARS-2-CoV severity, need for hospital admission or patient age were associated with IgG or IgM titres in multivariable models (p>0.1, Table S3).

Detection of SARS-CoV-2 antibodies by LFIA vs. RT-PCR
We first considered performance of the nine different LFIA devices using RT-PCR-confirmed cases as the reference standard (Table 1A, Figure S1) and considering any LFIA positive result (IgM, IgG or both) as positive. The LFIA devices achieved sensitivity ranging from 55% (95%CI 36-72%) to 70% (51-84%) and specificity from 95% (95%CI 86-99%) to 100% (94-100%). There was no evidence of differences between the devices in sensitivity (p≥0.015, cf. Benjamini-Hochberg p=0.0014 threshold) or specificity (p≥0.19 for all devices with at least one false-positive test). Restricting to 31 samples collected ≥10 days post symptom-onset (all ELISA IgG-positive), LFIA sensitivity ranged from 61% (95%CI 39-80%) to 88% (68-97%) (Table S4).

Detection of SARS-CoV-2 antibodies by LFIA vs. ELISA
We also considered performance relative to ELISA (Table S5, Figure S1), because the LFIA devices target the same antibodies. We considered patients positive by this alternative standard if their IgG OD reading exceeded the threshold above (since no samples were IgM-positive, IgG-negative). Sensitivity of antibody detection by LFIA ranged from 65% (95%CI 46-80%) to 85% (66-96%) and specificity from 93% (95%CI 83-98%) to 100% (94-100%); however, the device with the highest sensitivity had one of the lowest specificities (Figure S1). There was no evidence of differences in sensitivity (p≥0.010, cf. p=0.0014 threshold) or specificity between devices (p≥0.19).
Of 50 designated negative samples tested by both ELISA and the nine different LFIA devices, nine separate samples generated at least one false-positive, on seven different LFIA devices (Figure 3). Four samples generating false-positive results did so on more than one LFIA device, despite the absence of quantifiable IgM or IgG on ELISA, potentially suggesting a specific attribute of the sample causing a cross-reaction on certain LFIA platforms but not ELISA.

Of the 22 RT-PCR-positive samples collected in the acute setting, six fell below the ELISA detection threshold for IgM or IgG; two of these six were positive on LFIA testing, each on one (different) device. Of the remaining 16 acute samples (all ELISA IgG-positive), only nine were consistently positive across all nine LFIA devices. Due to limited availability of LFIA devices, fewer tests were performed on the 18 convalescent samples with available ELISA data, all with quantifiable IgG (Figure 2B;3A). Two had no antibody detected on any LFIA device, and only eight were consistently positive across all LFIA devices tested (between 1 and 9 devices tested per sample).

DISCUSSION

We here present the performance characteristics of a novel ELISA and nine LFIA devices for detecting SARS-COV-2 IgM and IgG using a panel of reference plasma. After setting thresholds for detection using 50 negative (pre-pandemic) controls, 85% of 40 RT-PCR-confirmed positive patients had IgG detected by ELISA, including 100% patients tested ≥10 days after symptom onset. A panel of LFIA devices had sensitivity between 55 and 70% against the reference-standard RT-PCRs, or 65-85% against ELISA, with specificity of 95-100% and 93-100% respectively. These estimates come with relatively wide confidence intervals due to constraints on the number of devices made available for testing. Nevertheless, this study provides a benchmark against which to further assess the performance of platforms to detect anti-SARS-CoV-2 IgM/IgG, with the aim of guiding decisions about deploying antibody testing and informing the design and assessment of second-generation assays.

LFIA devices are cheap to manufacture, store and distribute, and could be used as a point-of-care test by healthcare practitioners or individuals at home, offering an appealing approach to diagnostics and evaluating individual and population-level exposure. A positive antibody
test is currently regarded as a probable surrogate for immunity to reinfection. Secure confirmation of antibody status would therefore reduce anxiety, provide confidence to allow individuals to relax social distancing measures, and guide policy-makers in the staged release of population lock-down, potentially in tandem with digital approaches to contact tracing.\textsuperscript{14} As a diagnostic tool, serology may have a role in combination with RT-PCR testing to improve sensitivity, particularly of cases presenting sometime after symptom onset.\textsuperscript{15,16} Reproducible methods to detect and quantify vaccine-mediated anti-SARS-CoV-2 antibodies are also crucial, as vaccines enter clinical trials, evaluating the magnitude and durability of immunogenicity.

Appropriate thresholds for sensitivity and specificity of an antibody test depend on its purpose, and must be considered when planning deployment. For diagnosis in symptomatic patients, high sensitivity is required (generally $\geq 90\%$). Specificity is less critical as some false-positives could be tolerated (provided other potential diagnoses are considered, and accepting that over-diagnosis causes unnecessary quarantine or hospital admission). However, if antibody tests were deployed as an individual-level approach to inform release from quarantine, then high specificity is essential, as false-positive results return non-immune individuals to risk of exposure. For this reason, the UK Medicines and Healthcare products Regulatory Agency has set a minimum 98\% specificity threshold forLFIAs.\textsuperscript{17}

Appraisal of test performance should also consider the influence of population prevalence, acknowledging that this changes over time, geography and within different population groups (e.g. healthcare workers, teachers). The potential risk of a test providing false reassurance and release from lock-down of non-immune individuals can be considered as the proportion of all positive tests that are wrong, as well as the number of incorrect positive tests per 1000 people tested. Based on the working ‘best case’ scenario of a LFIA test with 70\% sensitivity and 98\% specificity, the proportion of positive tests that are wrong is 35\% at 5\% population seroprevalence (19 false-positives/1000 tested), 13\% at 20\% seroprevalence (16 false-positives/1000) and 3\% at 50\% seroprevalence (10 false-positives/1000) (Figure 4). However, more data are needed to investigate antibody-positivity as a correlate of protective immunity. Indeed pre-existing IgG could enhance disease in some situations,\textsuperscript{18} with animal data
demonstrating that SARS-CoV anti-spike IgG contributes to a proinflammatory response associated with lung injury in macaques.\textsuperscript{19}

Our data on the kinetics of antibody responses to SARS-CoV-2 infection build upon studies of hospitalised patients in China reporting a median 11 days to seroconversion for total antibody, with IgM and IgG seroconversion at days 12 and 14 respectively;\textsuperscript{15} another similar study reports 100\% IgG positivity by 19 days.\textsuperscript{16} Our ELISA data show IgG titres rose over the first 3 weeks of infection and that IgM testing identified no additional cases. Methods to enhance sensitivity, especially shortly after symptom onset, could consider different sample types (e.g. saliva), different antibody classes (e.g. IgA)\textsuperscript{20}, T-cell assays or antigen detection.\textsuperscript{21} In contrast to others,\textsuperscript{16,22-24} we did not find evidence of an association between disease severity and antibody titres. We observed several LFIA false positives, which may have potentially resulted from cross-reactivity of non-specific antibodies (e.g. reflecting past exposure to other seasonal coronavirus infections).

The main study limitation is that numbers tested were too small to provide tight confidence intervals around performance estimates for any specific LFIA device. Expanding testing across diverse populations would increase certainty, but given the broadly comparable performance of different assays, the cost and manpower to test large numbers may not be justifiable. Demonstrating high specificity is particularly challenging; for example, if the true underlying value was 98\%, 1000 negative controls would be required to estimate the specificity of an assay to +/-1\% with approximately 90\% power. Full assessment should also include a range of geographical locations and ethnic groups, children, and those with immunological disease including autoimmune conditions and immunosuppression.

In summary, antibody testing is crucial to inform release from lockdown. This study offers insights into the performance of both a novel ELISA and a panel of LFIA devices that have been made widely available, but to date with limited systematic validation. Our findings suggest that while current LFIA devices may provide some information for population-level surveys, their performance is inadequate for most individual patient applications. The biobank of samples assembled for this study continues to be expanded and will provide a valuable resource for developing the next generation of ELISA and lateral flow assays. The ELISA we
describe is currently being optimised and adapted to run on a high-throughput platform and provides promise for the development of reliable approaches to antibody detection that can support decision making for clinicians, the public health community, policy-makers and industry.
DATA AVAILABILITY
Results generated for all samples and relevant metadata is provided in Table S6.

ACKNOWLEDGEMENTS
This work uses data and samples provided by patients and collected by the NHS as part of their care and support. We are extremely grateful to the frontline NHS clinical and research staff and volunteer medical students, who collected this data in challenging circumstances; and the generosity of the participants and their families for their individual contributions.

AUTHOR CONTRIBUTIONS
Leadership roles were undertaken by DC (project management), RJP and DJR (management of pre-pandemic negative sample bank), AJM (identification and recruitment of cases), DWE and PCM (oversight of LFIA, data analysis and manuscript writing), GRS (ELISA design, development and data generation). All authors contributed as follows: JIB, JKB, DC, DWE, PCM, AJM, TEAP, GRS, MGS, ASW conceived and designed the study. EA, RA, MIA, MAi, JKB, SB, EC, TdS, AE, DG, AH, KJ, RL, UL, HM, AJM, JMa, JMi, MFM, SM, MO, RJP, AP, EP, TPr, DR, AS, MGS, DSk, JS, TS, VS, HT, PT, LT, CW, NW collected the clinical data and patient samples. KA, SKC, WD, KED, CD, AK, CL, CLC, JMo, JR, DSt, GRS, PS, BW obtained the laboratory data. DWE, PCM, TEAP, ASW analysed the data. DC, DWE, PCM, TEAP, ASW wrote the manuscript. EB, JB, TB, MC, RC, DC, HF, SH, PK, JK, CK, PCM, AJM, FP, DSt, GRS, ENS, JW provided study management and governance. All authors reviewed and approved the final version of the manuscript for submission.
AUTHOR LIST AND AFFILIATIONS

In alphabetical order:
Emily Adams¹, Mark Ainsworth², Rekha Anand MD³, Monique I Andersson MD², Kathryn Auckland PhD⁴, J Kenneth Baillie⁵, Eleanor Barnes PhD²,⁴, Sally Beer², John I Bell FRS⁴, Tamsin Berry MA⁶, Sagida Bibi PhD⁴, Miles Carroll PhD⁴,⁷, Senthil K Chinnakannan PhD⁸, Elizabeth Clutterbuck PhD⁴, Richard J Cornell FMedSci FRCP²,⁴, Derrick W Crook MBBCh²,⁴, Thushan de Silva PhD⁸, Wanwisa Dejnirattisai PhD⁴, Kate E Dingle PhD⁴, Christina Dold PhD⁴, Alexis Espinosa², David W Eyre BMBCh DPhil²,⁴, Helen Farmer MA⁶, Maria Fernandez Mendoza², Dominique Georgiou², Sarah J Hoosdally PhD⁴, Alistair Hunter BA⁹, Katie Jeffrey PhD², Paul Kleenerman FMedSci²,⁴, Julian Knight DPhil²,⁴, Clarice Knowles MA⁶, Andrew J Kwok MBChB⁴, Ulrich Leuschner MSc¹⁰, Robert Levin¹¹, Chang Liu PhD⁴, César López-Camacho PhD⁴, Jose Martinez², Phillipa C Matthews DPhil²,⁴, Hannah McGivern MSc¹², Alexander J Mentzer DPhil²,⁴, Jonathan Milton BSc¹², Juthathip Mongkolsapaya DPhil⁴, Shona C Moore PhD¹, Marta S Oliveira BTEC¹², Fiona Pereira PhD¹³, Elena Perez², Timothy Peto FRCP²,⁴, Rutger J Ploeg PhD FRC⁵,¹², Andrew Pollard FRCPC PHD²,¹⁴, Tessa Prince PhD³, David J Roberts FRCPath¹⁰, Justine K Rudkin PhD⁴, Veronica Sanchez², Gavin R Screaton⁴, Malcolm G Semple PhD¹, Donal T Skelly PhD²,¹⁵, Elliot Nathan Smith PGDip BA⁶, Alberto Sobrinodiaz², Julie Staves BSc², David I Stuart PhD⁴,¹⁶, Piyada Supasa⁴, Tomas Surik MSc¹², Hannah Thraves², Pat Tsang MSc¹⁰, Lance Turtle PhD MRCP¹, A Sarah Walker PhD⁴, Beibei Wang PhD⁴, Charlotte Washington MBChB³, Nicholas Watkins PhD¹⁷, James Whitehouse MSc⁶

¹ Liverpool School of Tropical Medicine, Liverpool, L3 5QA, UK
² Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK
³ NHS Blood and Transplant Birmingham, Vincent Drive, B15 2SG, UK
⁴ Nuffield Department of Medicine and NIHR Oxford Biomedical Research Centre, University of Oxford, OX3 9DU, UK
⁵ Roslin Institute, University of Edinburgh, EH25 9RJ, UK
⁶ Department of Health and Social Care, UK Government, London, UK
⁷ Porton Down, Public Health England, Salisbury, SP4 0JG
⁸ Department of Infection, Immunity and Cardiovascular Disease, The Medical School, University of Sheffield, Sheffield, S10 2RX, UK
⁹ NHS Blood and Transplant Basildon, Burnt Mills Industrial Estate, Basildon, SS13 1FH, UK
¹⁰ NHS Blood and Transplant Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK
11 Worthing Hospital, Worthing, BN11 2DH, UK
12 Nuffield Department of Surgical Sciences, University of Oxford, OX3 9DU, UK
13 Imperial College, London, SW7 2AZ, UK
14 Department of Paediatrics, University of Oxford, OX3 9DU, UK
15 Nuffield Department of Clinical Neurosciences, University of Oxford, OX3 9DU, UK
16 Diamond Light Source, Harwell Science and Innovation Campus, OX11 ODE, UK
17 NHS Blood and Transplant Cambridge, Long Road, Cambridge, CB2 0PT, UK
FUNDING

This study was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, the UK Government Department of Health and Social Care and grants from NIHR [award CO-CIN-01] and the Medical Research Council [grant MC_PC_19059]. DC, TEAP and ASW are supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with Public Health England (NIHR200915). Blood donor and QUOD samples were provided with support from NHS Blood and Transplant and the Medical Research Council UK. SKC is supported by Medical Research Council UK. TdS is funded by a Wellcome Trust Intermediate Clinical Fellowship (110058/Z/15/Z). DWE is a Robertson Trust Clinical Research Fellow and NIHR Oxford BRC Senior Research Fellow. PM is a Wellcome Trust Clinical Research Fellow (110110/Z/15/Z) and NIHR Oxford BRC Senior Research Fellow. AM, PK, SCM, TPr, MGS and LT are supported by NIHR Health Protection Research Unit in Emerging and Zoonotic Infections (HPRU-EZI) at University of Liverpool in partnership with Public Health England (PHE), in collaboration with the University of Oxford and Liverpool School of Tropical Medicine (award number NIHR200907). EB, PK, AJP and ASW are NIHR Senior Investigators. PK (WT109965/MA) and GRS (095541/A/11/Z) are Wellcome Trust Senior Investigators. JR is supported by a Sir Henry Dale Fellowship, jointly funded by the Wellcome Trust and the Royal Society (Grant 101237/Z/13/B). The views expressed are the author(s) and are not necessarily those of the NHS, the NIHR, the UK Department of Health and Social Care, the MRC or PHE.

DECLARATIONS

RC reports personal fees and other from MIROBIO Ltd, outside the submitted work. DWE reports personal fees from Gilead, outside the submitted work. SH reports grants from NIHR, during the conduct of the study. AJP reports grants from NIHR Oxford Biomedical Research Centre, outside the submitted work; and AJP is Chair of UK Dept. Health and Social Care’s (DHSC) Joint Committee on Vaccination & Immunisation (JCVI) and is a member of the WHO’s SAGE. The views expressed in this article do not necessarily represent the views of DHSC, JCVI, NIHR or WHO. MGS reports grants from National Institute of Health Research, grants from Medical Research Council UK, grants from Health Protection Research Unit in Emerging & Zoonotic Infections, University of Liverpool, during the conduct of the study; other from
Integrum Scientific LLC, Greensboro, NC, USA, outside the submitted work. ASW reports grants from NIHR, during the conduct of the study. No other author has a conflict of interest to declare.
TABLES

Table 1. Results of nine lateral flow immunoassays (LFIA) devices and an ELISA assay, tested with plasma classified as positive (RT-PCR positive) and negative (pre-pandemic). n=91-182 per LFIA device. Different manufacturers are designated 1-9. 95% confidence intervals (CI) are presented for each point estimate. Any LFIA positive result (IgM, IgG or both) was considered positive. ELISA positive samples were all positive for IgG, no sample was IgM-positive and IgG-negative.

<table>
<thead>
<tr>
<th>Assay</th>
<th>RT-PCR positive</th>
<th>Pre-pandemic control</th>
<th>Sensitivity (95% CI)</th>
<th>Specificity (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>True positive</td>
<td>False negative</td>
<td>True negative</td>
<td>False positive</td>
</tr>
<tr>
<td>ELISA</td>
<td>34</td>
<td>6</td>
<td>50</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>85 (70,94)</td>
<td>100 (93,100)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>18</td>
<td>15</td>
<td>60</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>55 (36,72)</td>
<td>100 (94,100)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>23</td>
<td>15</td>
<td>90</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>61 (43,76)</td>
<td>99 (94,&gt;99)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>21</td>
<td>12</td>
<td>58</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>64 (45,80)</td>
<td>97 (88,&gt;99)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>25</td>
<td>13</td>
<td>59</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>66 (49,80)</td>
<td>98 (91,&gt;99)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>19</td>
<td>12</td>
<td>58</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>61 (42,78)</td>
<td>97 (91,&gt;99)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>20</td>
<td>11</td>
<td>59</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>65 (45,81)</td>
<td>98 (91,&gt;99)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>23</td>
<td>10</td>
<td>57</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>70 (51,84)</td>
<td>95 (86,&gt;99)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>18</td>
<td>14</td>
<td>60</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>56 (38,74)</td>
<td>100 (94,100)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>22</td>
<td>18</td>
<td>138</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>55 (38,74)</td>
<td>97 (93,&gt;99)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
FIGURES

Figure 1: Cartoon to illustrate the generation of IgM and IgG antibodies to SARS nCoV-2 and detection of antibodies by a lateral flow device. (A) *In vivo* generation of antibodies to the trimeric SARS-CoV-2 spike protein. (B) Projected change in titres of specific IgM and IgG over time following infection, with arrows indicating typical time frames for collection of acute and convalescent samples. (C) *Ex vivo* detection of IgG and/or IgM using a lateral flow immunoassay (LFIA): S= sample well, T=test antibody; C=control. Diagram shows a positive sample on the left, with positive lines at both C and T, and a negative test on the right with a line present only at C. Any other combination of lines renders the test invalid. Some devices have two test lines, for separate detection of anti-SARS-nCoV-2-IgG and -IgM. (D) Outcomes of testing negative and positive plasma using LFIA. (E) Calculation of sensitivity, specificity, positive and negative predictive value of a test. Image created with BioRender.com; exported under a paid subscription.
Figure 2: Results of testing 90 plasma samples for SARS-CoV-2 IgM and IgG by Enzyme linked Immunosorbent Assay (ELISA). (A) IgM readings for SARS-CoV-2 pre-pandemic plasma (designated negatives, shown in blue, n=50), and RT-PCR confirmed cases of SARS-CoV-2 infection (designated positives, shown in orange, n=40; divided into acute cases, n=22, and convalescent cases, n=18. Threshold of OD = 0.4 discriminates accurately between negative controls and convalescent sera. (B) IgG data shown for the same subgroups described for panel A. A threshold of OD = 0.07 discriminates between designated negatives and positives. (C) IgM OD values plotted against the time post symptoms at which plasma was obtained. The line shows the mean OD value expected from a spline-based linear regression model, the ribbon indicates the pointwise 95% confidence interval. (D) IgG OD values plotted against the time post symptoms at which plasma was obtained. Coloured dots in panels C and D indicate disease severity. OD = optical density.
**ELISA OD reading: IgM**

- **Pre-pandemic control**
- **PCR-positive case (<=28 days from symptom onset)**
- **Convalescent PCR-positive case (>28 days from symptom onset)**

**ELISA OD reading: IgG**

- **Pre-pandemic control**
- **PCR-positive case (<=28 days from symptom onset)**
- **Convalescent PCR-positive case (>28 days from symptom onset)**

---

**Expected result**

- **Negative**
- **Positive**

---

**Infection severity**

- **Mild**
- **Asymptomatic**
- **Severe**
- **Critical**
**Figure 3:** Comparison between ELISA and LFIA for SARS-CoV-2 designated negative and positive plasma. Panel A shows quantitative optical density (OD) readout from ELISA for IgG for designated negative plasma (n=50) and from individuals with RT-PCR confirmed infection (n=40, divided into acute and convalescent plasma). IgM results are shown in Figure S2 in the Supplementary Materials. Panel B shows results from LFIA produced by nine manufacturers. Any positive test for IgG, IgM, both or total antibody is shown as positive, please see Figure S2 for more detailed breakdown. Grey blocks indicate missing data as a result of insufficient devices to test all samples and one assay on one device with an invalid result. Samples in both panels are ranked from left to right by quantitation of IgG (as indicated in panel A).
Figure 4: Influence of population prevalence of seropositivity on assay performance.

Scenarios with population prevalence of 5%, 20% and 50% are shown within each panel. Panel A shows the proportion of all positive tests that are wrong (1-positive predictive value), which would lead to false release from lock-down of non-immune individuals, for varying test sensitivity (x-axis) and 1-specificity (line colour). Panel B shows the proportion of negative tests that are wrong, panel C the absolute number of false positive tests per 1000 tests and panel D the absolute number of false negative tests per 1000 tests.
REFERENCES


